rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LRMR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Leerink reiterates Larimar Therapeutics stock rating at Outperform
      13h agoInvesting.comLRMR
      Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
      Nov 16Yahoo FinanceLRMR
      Larimar Therapeutics CFO Celano purchases $49,991 in stock
      Nov 13Investing.comLRMR
      Larimar Therapeutics chief development officer buys $13,549 in stock
      Nov 13Investing.comLRMR
      Larimar Therapeutics director Thomas Hamilton buys $187,082 in shares
      Nov 13Investing.comLRMR
      Larimar Therapeutics president and CEO Carole Ben-Maimon acquires $49,953 in stock
      Nov 13Investing.comLRMR
      Larimar Therapeutics director purchases $21,800 in shares
      Nov 12Investing.comLRMR
      Larimar Therapeutics director Joseph Truitt buys $9,791 in shares
      Nov 12Investing.comLRMR
      Larimar Therapeutics president John Harlow buys $49,918 in shares
      Nov 12Investing.comLRMR
      Wedbush reiterates Larimar Therapeutics stock rating at Outperform
      Nov 10Investing.comLRMR
      Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
      Nov 5Yahoo FinanceLRMR
      Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 4Yahoo FinanceLRMR
      Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO
      Sep 29Investing.comLRMR
      Larimar Therapeutics names John Harlow president and COO
      Sep 29Investing.comLRMR
      Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

      BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex

      Sep 29Yahoo FinanceLRMR
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

      Tipranks Press Release.

      Sep 29The Globe and MailLRMR
      Larimar Therapeutics Names John Harlow COO
      Sep 29Yahoo FinanceLRMR

      This is the newest page. Registered accounts read further back.